Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Dr. Daneshmand reviews data from ENVISION on mytomycin for patients with intermediate-risk bladder cancer.
ANKTIVA plus BCG shows a 71% CR rate and up to 54 months of durable response in patients with BCG-unresponsive NMIBC-CIS.
Sequential chemotherapy has been increasingly used as a 1st-line treatment option for NMIBC due to the ongoing BCG shortage.
UGN-102 could become the first FDA-approved therapy for low-grade intermediate-risk non-muscle invasive bladder cancer.
Drs. Karine Tawagi and Christopher Wallis review the SunRISe-1 and AMBASSADOR trials at the ESMO Congress 2024.
Results of SunRISe-1 provide support for TAR-200 monotherapy in patients with BCG-unresponsive high-risk NMIBC.
Dr. Daneshmand shares his thoughts on alternative intravesical therapies in NMIBC and how they compare for efficacy, safety.
If approved, mitomycin is anticipated to become the first FDA-approved treatment for LG-IR-NMIBC.
Dr. Sia Daneshmand highlights latest advancements in bladder preservation strategies for patients with NMIBC.
BCG is ineffective in 30% to 77% of patients, and many experience disease recurrence within 5 years.
Researchers evaluated the data of 50 specimens from patients who underwent TURBT and cystectomy for UC.
Dr. Prasad provides updates on the positive DOR data observed with UGN-102 for LG-IR-NMIBC in the ENVISION trial.
UroGen began the process of a rolling New Drug Application to the FDA for mitomycin as a treatment for patients with NMIBC.
Dr. Li describes his post hoc analysis and findings regarding patients with BCG–unresponsive, high-risk NMIBC in ...
Dr. Li details the final results of CORE-001, a phase-2, single arm study of cretostimogene combined with pembrolizumab.
Urinary tumor DNA predicts residual bladder cancer pre-surgery, improving assessments and treatment, ASCO 2024 study finds
The CORE-001 trial began in 2020 to study the breakthrough therapy cretostimogene with pembrolizumab for high-risk NMIBC.
Dr. Li rationalizes the design and potential impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Dr. Li provides commentary on the rationale, design, and impact of the MoonRISe-1 study for intermediate-risk NMIBC.
The primary end point of the analysis of cohort B was 12-month disease-free survival.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.